Glucagon-Like Peptide-1 Receptor Agonists and Risk of Gastrointestinal Cancers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
胰高血糖素樣肽-1 受體激動劑與胃腸道癌症風險:隨機對照試驗的系統性回顧與統合分析。
Pharmacol Res 2024-09-09
Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.
葡萄糖樣肽-1 受體激動劑與胰臟癌的潛在風險:使用FDA不良事件報告系統和文獻可視化分析的藥物監察研究。
Int J Clin Pharm 2023-12-13
GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.
GLP-1RAs 引起腸胃不良反應的藥物停用:系統回顧和網絡荟萃分析。
Front Endocrinol (Lausanne) 2023-10-30
Glucagon-Like Peptide-1 Receptor Agonist and Risk of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.
二型糖尿病患者中胰高血糖素樣肽-1受體激動劑與糖尿病視網膜病變風險:隨機安慰劑對照試驗的系統性回顧和荟萃分析。
Clin Drug Investig 2023-12-16
Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials.
糖尿病患者甲狀腺癌風險:一項隨機對照試驗的系統性回顧和荟萃分析。
Diabetes Obes Metab 2024-02-06
Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes.
二型糖尿病患者中胰臟癌風險與葡萄糖樣肽-1受體激動劑的關聯。
JAMA Netw Open 2024-01-08
Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials.
葡萄糖樣肽-1 受體激動劑與癌症風險的關聯性:來自藥物靶點 Mendelian 隨機化和臨床試驗的證據。
Int J Surg 2024-05-03
The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study.
糖尿病患者使用 GLP-1 受體激動劑不會增加胰臟癌風險:美國基礎的世代研究。
Cancers (Basel) 2024-05-13